XBiotech closed at $1.95 on Nov 4, down 2.01%, 33.7% below its 52-week closing high. Volume of 94.3K shares was 0.95× its 20-day average (close to normal).
Split-adjusted performance: -9.7% over one month, -23.5% over six months, -14.8% over one year.
Short interest was 300.9K shares at the Oct 15 settlement, down 8.3% from the prior report (1.8% of float, 6.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| XBITXBiotech | $1.95 | −2.01% | −23.5% | — | — | — | $59.5M | |
| VRCAVerrica Pharmaceuticals | $3.46 | +5.02% | −59.0% | −53.8% | −224.4% | — | $59.4M | Compare |
| RNXTRenovoRx | $1.31 | +1.55% | +47.2% | +115.4% | −320.2% | — | $59.1M | Compare |
| CLNNClene | $4.10 | +8.75% | −42.7% | +233.3% | −14915.6% | — | $58.3M | Compare |
| GOSSGossamer Bio | $9.95 | +7.22% | −64.5% | −19.6% | 182.9% | — | $60.9M | Compare |
| NMADNomad Power Solutions | $3.60 | +2.27% | — | — | — | — | $58.0M | Compare |
| CTORCitius Oncology | $0.5470 | −0.55% | −39.8% | — | −597.4% | — | $57.9M | Compare |
| XLOXilio Therapeutics | $8.71 | +0.35% | +10.3% | +131.2% | −34.1% | — | $57.3M | Compare |
| RNTXRein Therapeutics | $0.6587 | −1.32% | −43.7% | — | — | — | $56.8M | Compare |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
